Diagnosis of bone metastasis: Recent comparative studies of imaging modalities

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 55, Issue 4, 2011, Pages 374-410

  Talbot, J N ^a   Paycha, F ^b   Balogova, S ^c  

^a HÔPITAL TENON   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c Physics and Informatics   (Slovakia)

Author keywords

Bone and bones; Comparative study; Diagnostic imaging; Magnetic resonance imaging; Neoplasm metastatis; Tomography, X ray computed

Indexed keywords

ACETIC ACID; BIOLOGICAL MARKER; CHOLINE; FLUOROCHOLINE F 18; FLUORODEOXYGLUCOSE F 18; FLUORODIBYDROTESTOSTERONE; FLUOROESTRADIOL F 18; PENTETREOTIDE; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT; TECHNETIUM 99M; UNCLASSIFIED DRUG;

AGGRESSIVENESS; BONE METABOLISM; BONE METASTASIS; BONE PAIN; BONE SCINTISCANNING; BREAST CANCER; CIRCULATING TUMOR CELL; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DIFFUSION WEIGHTED IMAGING; DIGESTIVE SYSTEM CANCER; ECHOGRAPHY; GYNECOLOGIC CANCER; HEAD AND NECK CANCER; HUMAN; KIDNEY CARCINOMA; LIVER CANCER; LUNG CANCER; MEDICAL LITERATURE; MELANOMA; MULTIDETECTOR COMPUTED TOMOGRAPHY; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS CANCER; PATIENT CODING; PERFORMANCE; POSITRON EMISSION TOMOGRAPHY; PRIMARY MEDICAL CARE; PROSTATE CANCER; REVIEW; SCINTIGRAPHY; THYROID CANCER; TRANSITIONAL CELL CARCINOMA; X RAY;

BONE AND BONES; BONE NEOPLASMS; DIAGNOSTIC IMAGING; HUMANS; MAGNETIC RESONANCE IMAGING; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIONUCLIDE IMAGING; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 80755188051     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (251)

1. Ferlay J, Parkin DM, Stellarova-Foucher E. Estimates of the cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010;46:765-81.
2. Ghanem N, Uhl M, Brink I et al. Diagnostic value of MRI in comparison to scintigraphy, PET, MS-CT and PET/CT for the detection of metastases of bone. Eur J Radiol 2005;55:41-55. (Pubitemid 40798487)
3. Pilge H, Holzapfel BM, Prodinger PM et al. Diagnostics and therapy of spinal metastases. Orthopade 2011;40:185-93
4. Hage WD, Aboulafia AJ, Aboulafia DM. Incidence, location, and diagnostic evaluation of metastatic bone disease. Orthop Clin North Am 2000;31:515-28.
5. Rougraff BT. Evaluation of the patient with carcinoma of unknown origin metastatic to bone. Clin Orthop Relat Res 2003;(415 Suppl):S105-9. (Pubitemid 37323326)
6. Walker MP, Yaszemski MJ, Kim CW et al. Metastatic disease of the spine:evaluation and treatment. Clin Orthop Relat Res 2003;415 Suppl:S165-75.
7. Andreula C, Murrone M. Metastatic disease of the spine. Eur Radiol 2005;15.627-32.
8. White AP, Kwon BK, Lindskog DM et al. Metastatic disease of the spine. J Am Acad Orthop Surg 2006;14:587-98. (Pubitemid 44916623)
9. Arguello F, Baggs RB, Duerst RE et al. Pathogenesis of vertebral metastasis and epidural spinal cord compression. Cancer. 1990;65:98-106. (Pubitemid 20026818)
10. Schirrmeister H, Arslandemir C, Glatting G et al. Omission of bone scanning according to staging guidelines leads to futile therapy in non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2004;31:964-8. (Pubitemid 38915651)
11. Koizumi M, Yoshimoto M, Kasumi F et al. Post-operative breast cancer patients diagnosed with skeletal metastasis without bone pain had fewer skeletal-related events and deaths than those with bone pain. BMC Cancer 2010;10:423.
12. Montravers F, Younsi N, Rousseau C et al. Comparison of bone scanning and CA 15-3 serum concentration in the follow-up of breast cancer. Anticancer Res 1997;17(3B):1683-6. (Pubitemid 27263146)
13. Briganti A, Passoni N, Ferrari M et al. When to perform bone scan in patients with newly diagnosed prostate cancer:external validation of the currently available guidelines and proposal of a novel risk stratification tool. Eur Urol 2010;57:551-8.
14. Loeb S, Makarov DV, Schaeffer EM et al. Prostate specific antigen at the initial diagnosis of metastasis to bone in patients after radical prostatectomy. J Urol 2010;184:157-61.
15. Kobayashi T, Gabazza EC, Taguchi O et al. Type I collagen metabolites as tumor markers in patients with lung carcinoma. Cancer 1999;85:1951-7. (Pubitemid 29202769)
16. Horiguchi T, Tachikawa S, Kondo R et al. Usefulness of serum carboxy-terminal telopeptide of type I collagen (ICTP) as a marker of bone metastasis from lung cancer. Jpn J Clin Oncol 2000;30:174-9. (Pubitemid 30335821)
17. Leeming DJ, Delling G, Koizumi M et al. Alpha CTX as a biomarker of skeletal invasion of breast cancer: immunolocalization and the load dependency of urinary excretion. Cancer Epidemiol Biomarkers Prev 2006;15:1392-5. (Pubitemid 44125298)
18. Leeming DJ, Hegele A, Byrjalsen I et al. Biochemical markers for monitoring response to therapy:evidence for higher bone specificity by a novel marker compared with routine markers. Cancer Epidemiol Biomarkers Prev 2008;17:1269-76.
19. Kamiya N, Suzuki H, Yano M et al. Implications of serum bone turnover markers in prostate cancer patients with bone metastasis. Urology 2010;75:1446-51.
20. Schoenberger J, Rozeboom S, Wirthgen-Beyer E, Eilles C. Evaluation of the clinical value of bone metabolic parameters for the screening of osseous metastases compared to bone scintigraphy. BMC Nucl Med 2004;4:3.
21. Ebert W, Muley T, Herb KP et al. Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients. Anticancer Res 2004;24:3193-201. (Pubitemid 39390972)
22. Krebs MG, Sloane R, Priest L et al. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol 2011;29:1556-63.
23. De Giorgi U, Mego M, Rohren EM et al. 18F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer. J Nucl Med 2010;51:1213-8.
24. Saad A, Kanate A, Sehbai A et al. Correlation among [18F] fluorodeoxyglucose positron emission tomography/computed tomography, cancer antigen 27.29, and circulating tumor cell testing in metastatic breast cancer. Clin Breast Cancer 2008,8:357-61.
25. Panteleakou Z, Lembessis P, Sourla A et al. Detection of circulating tumor cells in prostate cancer patients:methodological pitfalls and clinical relevance. Mol Med 2009;15:101-14.
26. Ruffato A, Mattioli S, Pileri S et al. Do bone marrow isolated tumor cells influence long-term survival of non-small cell lung cancer? Eur J Cardiothorac Surg 2009;35:463-8.
27. Tjensvoll K, Oltedal S, Farmen RK et al. Disseminated tumor cells in bone marrow assessed by TWIST1, cytokeratin 19, and mammaglobin A mRNA predict clinical outcome in operable breast cancer patients. Clin Breast Cancer 2010;10(5):378-84.
28. Banys M, Solomayer EF, Becker S et al. Disseminated tumor cells in bone marrow may affect prognosis of patients with gynecologic malignancies. Int J Gynecol Cancer 2009:19948-52.
29. Weckermann D, Polzer B, Ragg T et al. Perioperative activation of disseminated tumor cells in bone marrow of patients with prostate cancer. J Clin Oncol 2009, 27:1549-1556.
30. Roberts CC, Daffner RH, Weissman BN et al. ACR appropriateness criteria on metastatic bone disease. J Am Coll Radiol 2010;7:400-9.
31. Schirrmeister H, Buck A, Guhlmann A, Reske SN. Anatomical distribution and sclerotic activity of bone metastases from thyroid cancer assessed with F-18 sodium fluoride Positron Emission Tomography. Thyroid 2001;11:677-683. (Pubitemid 32701589)
32. Talbot JN, Gutman F, Fartoux L et al. PET/CT in patients with hepatocellular carcinoma using [(18)F]fluorocholine:preliminary comparison with [(18)F]FDG PET/CT. Eur J Nucl Med Mo; Imaging 2006;33:1285-9. (Pubitemid 44630783)
33. Uematsu T, Yuen S, Yukisawa S et al. Comparison of FDG PET and SPECT for detection of bone metastases in breast cancer. AJR Am J Roentgenol 2005;184:1266-73. (Pubitemid 43821911)
34. Metser U, Lerman H, Blank A et al. Malignant involvement of the spine:assessment by 18F-FDG PET/CT. J Nucl Med 2004;45:279-84. (Pubitemid 47618649)
35. Beheshti M, Vali R, Waldenberger et al. Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CTa comparative study. Eur J Nucl Med Mol Imaging 2008;35:1766-74.
36. McCarthy M, Siew T, Campbell A et al. 18F-Fluoromethylcholine (FCH) PET imaging in patients with castration-resistant prostate cancer:prospective comparison with standard imaging. Eur J Nucl Med Mol Imaging 2011;38:14-22.
37. Ketelsen D, Röthke M, Aschoff P et al. Detection of bone metastasis of prostate cancer - comparison of whole-body MRI and bone scintigraphy. Rofo 2008;180:746-52.
38. Goudarzi B, Kishimoto R, Komatsu S et al. Detection of bone metastases using diffusion weighted magnetic resonance imagingcomparison with (11)C-methionine PET and bone scintigraphy. Magn Reson Imaging 2010;28:372-9.
39. Kao CH, Hsieh JF, Tsai SC et al. Comparison and discrepancy of 18F-2-deoxyglucose positron emission tomography and Tc-99m MDP bone scan to detect bone metastases. Anticancer Res 2000;20:2189-92. (Pubitemid 30636206)
40. Nemeth AJ, Henson JW, Mullins ME et al. Improved detection of skull metastasis with diffusion-weighted MR imaging. AJNR Am J Neuroradiol 2007;28:1088-92. (Pubitemid 46984548)
41. Phan HT, Jager PL, Plukker JT et al. Detection of bone metastases in thyroid cancer patients:bone scintigraphy or 18F-FDG PET? Nucl Med Commun 2007;28:597-602. (Pubitemid 47067046)
42. Gönen M, Partageas KS, Larson SM. Statistical issues in analysis of diagnostic imaging experiments with multiple observations per patient. Radiology 2001;221:763-7. (Pubitemid 33101770)
43. Obuchowski NA. On the comparison of correlated proportions for clustered data. Stat Med 1998;17:1495-507. (Pubitemid 28330346)
44. Ciaschini MW, Remer EM, Baker ME et al. Urinary calculi: radiation dose reduction of 50% and 75% at CT - effect on sensitivity. Radiology 2009;251:105-11.
45. European Medicines Agency. Guideline on clinical evaluation of diagnostic agents. CPMP/EWP/1119/98/Rev 1 2009.
46. Whiting P, Rutjes AWS, Reitsma JB et al. The development of QUADAS:a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Medical Research Methodology 2003;3:25.
47. Reitsma JB, Rutjes AWS, Whiting P et al. Chapter 9:Assessing methodological quality. In:Deeks JJ, Bossuyt PM, Gatsonis C (editors), Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy Version 1.0.0. The Cochrane Collaboration, 2009 [Internet]. Available from:http://srdta.cochrane. org/ [cited 2011, May 3D.
48. Tatehishi U, Morita S, Taguri M et al. A meta-analysis of (18F)-fluoride positrom emission tomography for assessement of metastatic bone tumor. Ann Nucl Med 2010;24:523-31.
49. Liu T, Xu JY, Xu W et al. Fluorine-18 deoxyglucose Positron Emission Tomography, Magnetic Resonance Imaging and Bone Scintigraphy for the diagnosis of bone metastases in patients with lung cancer:Which one is the best? - a meta-analysis. Clin Oncol (R Coll Radiol) 2011;23:350-8.
50. Liu T, Cheng T, Xu W, Yan WL et al. A meta-analysis of (18) FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with breast cancer. Skeletal Radiol 2011;40:523-31.
51. Edelstyn GA, Gillepsie PJ, Grebbell FS. The radiological demonstration of osseous metastases. Experimental observations. Clin Radiol 1967;18:158-62.
52. Watanabe H, Sato T, Hisinuma T et al. Comparison of MRI, CT and bone scintigraphy in metastases of experimental neoplasm. Tohoku J Exp Med 1991;163:229-31.
53. Karnholz R, Sze G. Current imaging in spinal metastatic disease. Semin Oncol 1991;18:158-69.
54. Rosenthal DI. Radiologic diagnosis of bone metastases. Cancer 1997;80:1595-607. (Pubitemid 27444032)
55. Hasuo K, Uchino A, Matsumoto S et al. MR imaging compared with CT, angiography, and myelography supplemented with CT in the diagnosis of spinal tumors. Radiat Med 1993;11:177-86. (Pubitemid 24000372)
56. Sauvage PJ, Thivolle P, Noel JB et al. MRI in the early diagnosis of spinal metastases of bronchial cancer. J Radiol 1996;77:185-90. (Pubitemid 26103495)
57. Kosuda S, Kaji T, Yokoyama H et al. Does bone SPECT actually have lower sensitivity for detecting vertebral metastasis than MRI? J Nucl Med 1996:37:975-8. (Pubitemid 126447133)
58. Fukuda Y, Ando K, Ishikura R. Superparamagnetic iron oxide (SPIO) MRI contrast agent for bone marrow imaging:differentiating bone metastasis and osteomyelitis. Magn Reson Med Sci 2006;5.191-6.
59. Melton LJ 3d. Epidemiology of spinal osteoporosis. Spine 1997;22(24 Suppl):2S-11S.
60. Simpfendorfer CS, Ilaslan H, Davies AM et al. Does the presence of focal normal marrow fat signal within a tumor on MRI exclude malignancy? An analysis of 184 histologically proven tumors of the pelvic and appendicular skeleton. Skeletal Radiol 2008;37:797-804.
61. Shih WJ, Kwolek DS, Lahr B. Testicular lymphoma with bone/bone marrow metastases illustrated by scrotal sonography, spinal MRI, and total body Tc-99m HMDP and Tc-99m MIBI images. Ann Nucl Med 1999;13:293-7.
62. Jung HS, Jee WH, McCauley TR et al. Discrimination of metastatic from acute osteoporotic compression spinal fractures with MR imaging. Radiographics 2003;23:179-87. (Pubitemid 37421448)
63. Uetani M, Hashmi R, Hayashi K. Malignant and benign compression fractures:differentiation and diagnostic pitfalls on MRI. Clin Radiol 2004;59:124-31. (Pubitemid 38159838)
64. Lecouvet FE, Simon M, Tombal B et al. Whole-body MRI (WB-MRI) versus axial skeleton MRI (AS-MRI) to detect and measure bone metastases in prostate cancer (PCa). Eur Radiol 2010;20:2973-82.
65. Moon WJ, Lee MH, Chung EC. Diffusion-weighted imaging with sensitivity encoding (SENSE) for detecting cranial bone marrow metastases:comparison with T1-weighted images. Korean J Radiol 2007;8:185-91.
66. Byun WM, Jang HW, Kim SW et al. Diffusion-weighted magnetic resonance imaging of sacral insufficiency fractures:comparison with metastases of the sacrum. Spine (Phila Pa 1976) 2007;32:E820-4.
67. Paik SH, Chung MJ, Park JS et al. High-resolution sonography of the rib:can fracture and metastasis be differentiated? AJR Am J Roentgenol 2005;184:969-74 (Pubitemid 43899530)
68. Taoka T, Mayr NA, Lee HJ et al. Factors influencing visualization of vertebral metastases on MR imaging versus bone scintigraphy. AJR 2001;176:1525-30. (Pubitemid 32510275)
69. Freeman SJ, Sonoda LI, Seshadri N et al. What is the significance of solitary bony abnormalities on bone scintigrams of children with malignancy? Pediatr Hematol Oncol 2010;27:380-6.
70. Sadik M, Suurkula M, Höglund P et al. Improved classifications of planar whole-body bone scans using a computer-assisted diagnosis system:a multicenter, multiple-reader, multiple-case study. J Nucl Med 2009;50:368-75.
71. Schimming R, Juengling FD, Altehofer C, et al. Diagnosis of questionable mandibular infiltration by squamous epithelial carcinomas. 3-D 99mTc-DPD SPECT reconstruction and (18F) fluoride PET study:diagnostic advantages or unnecessary expense? HNO 2001;49:355-360.
72. Han LJ, Au-Yong TK, Tong WC et al. Comparison of bone single-photon emission tomography and planar imaging in the detection of vertebral metastases in patients with back pain. Eur J Nucl Med 1998;25:635-8. (Pubitemid 28297839)
73. Helyar V, Mohan HK, Barwick T et al. The added value of multislice SPECT/CT in patients with equivocal bony metastasis from carcinoma of the prostate. Eur J Nucl Med Mol Imaging 2010;37:706-13.
74. Romer W, Nömayr A, Uder Met al. SPECT-guided CT for evaluating foci of increased bone metabolism classified as indeterminate on SPECT in cancer patients. J Nucl Med 2006;47:1102-1106. (Pubitemid 47544905)
75. Ndlovu X, George R, Ellmann A et al. Should SPECT-CT replace SPECT for the evaluation of equivocal bone scan lesions in patients with underlying malignancies? Nucl Med Commun 2010;31:659-65.
76. Toegel S, Hoffmann O, Wadsak W et al. Uptake of bone-seekers is solely associated with mineralization ! A study with (99m) Tc-MDP, (153)Sm-EDTMP and fluoride-(18F) on osteoblasts. Eur J Nucl Med Mol Imaging 2006;33:491-494.
77. Blau M, Nagler W, Bender MA. A new isotope for bone scanning. J Nucl Med 1962;3:332-4.
78. Tayama Y, Takahashi N, Oka T et al. Clinical evaluation of the effect of attenuation correction technique on 18F-fluoride PET images. Ann Nucl Med 2007;21:93-9. (Pubitemid 46495608)
79. Kawaguchi M, Tateishi U, Shizukuishi K et al. 18F-fluoride uptake in bone metastasis:morphologic and metabolic analysis on integrated PET/CT. Ann Nucl Med 2010;24:241-7.
80. Even-Sapir E, Metser U, Flusser Gr al. Assessment of malignant skeletal disease:initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT. J Nucl Med 2004;45:272-8. (Pubitemid 47618648)
81. Du Y, Cullum I, Illidge TM, EH PJ. Fusion of metabolic function and morpho!ogy:sequential [18F]fluorodeoxyglucose positron-emission tomography/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer. J Clin Oncol 2007;25:3440-7. (Pubitemid 47310881)
82. Vogler JB 3rd, Murphy WA. Bone marrow imaging. Radiology 1988;168:679-93.
83. Hollinger EF, Alibazoglu H, Ali A et al. Hematopoietic cytokine-mediated FDG uptake simulates the appearance of diffuse metastatic disease on whole-body PET imaging. Clin Nucl Med 1998;23:93-8. (Pubitemid 28104051)
84. Plantade A, Montravers F, Selle F et al. Diffusely increased F-18 FDG uptake in bone marrow in a patient with acute anemia and recent erythropoietin therapy. Clin Nucl Med 2003;28:771-2. (Pubitemid 38295208)
85. Elzinga EH, van der Laken CJ, Comans EF et al. 2-Deoxy-2-[F-18]fluoro-D- glucose joint uptake on positron emission tomography images:rheumatoid arthritis versus osteoarthritis. Mol Imaging Biol 2007;9:357-60.
86. Ohtori S, Suzuki M, Koshi T et al. 18F-fluorodeoxyglucose-PET for patients with suspected spondylitis showing Modic change. Spine (Phila Pa 1976) 2010;35:E1599-603.
87. de Prost N, Kerrou K, Sibony M et al. Fluorine-18 fluorode-oxyglucose with positron emission tomography revealed bone marrow involvement in sarcoidosis patients with anaemia. Respiration 2010;79:25-31.
88. Even-Sapir E. Imaging of malignant bone involvement by morphologic, scintigraphic, and hybrid modalities. J Nucl Med 2005;46:1356-67. (Pubitemid 43733488)
89. Rosen RS, Fayad L, Wahl RL. Increased 18F-FDG uptake in degenerative disease of the spine:characterization with 18F-FDG PET/CT. J Nucl Med 2006;47:1274-80. (Pubitemid 47544879)
90. Nakamoto Y, Cohade C, Tatsumi M et al. CT appearance of bone metastases detected with FDG PET as part of the same PET/CT examination. Radiology 2005;237:627-34. (Pubitemid 41507904)
91. Taira AV, Herfkens RJ, Gambhir SS et al. Detection of bone metastases:assessment of integrated FDG PET/CT imaging. Radiology 2007;243:204-11. (Pubitemid 46579712)
92. Hoegerle S, Juengling F, Otte A et al. Combined FDG and [F-18] Fluoride whole-body PET:a feasible two-in-one approach to cancer imaging. Radiology 1998;209:253-8. (Pubitemid 28464675)
93. Iagaru A, Mittra E, Yaghoubi SS et al. Novel strategy for a cocktail 18F-Fluoride and 18F-FDG PET/CT scan for evaluation of malignancy: Results of the pilot-phase study. J Nucl Med 2009;50:501-5.
94. Basu S, Rao R. Combined 18F-FDG and fluoride approach in PET/CT imaging.is there a clinical future ? J Nucl Med 2010;5:165.
95. Langsteger W, Heinisch M, Fogelman I. The role of fluorodeoxyglucose, 18F-dihydroxyphenylalanine, 18F-choline, and 18F-fluoride in bone imaging with emphasis on prostate and breast. Semin Nucl Med 2006;36:73-92. (Pubitemid 41782168)
96. Groves AM, Beadsmoore CJ, Cheow HK et al. Can 16-detector multislice CT exclude skeletal lesions during tumour staging? Implications for the cancer patient. Eur Radiol 2006;16:1066-73.
97. Nakahara T, Suzuki T, Kitamura N, Kubo A. Bone scintigraphy is really unnecessary for evaluation of bone metastasis? Eur Radiol 2008;18:2676-7.
98. Schirrmeister H, Guhlmann A, Eisner K et al. Sensitivity in detecting osseous lesions depends on anatomic loca-lization: planar bone scintigraphy versus 18F PET. J Nucl Med 1999;40:1623-9. (Pubitemid 29471151)
99. Withofs N, Grayet B, Tancredi T et al. 18F-fluoride PET/CT for assessing bone involvement in prostate and breast cancers. Nucl Med Commun 2011;32:168-76.
100. Hur J, Yoon CS, Ryu YH et al. Accuracy of fluorodeoxyglucose-positron emission tomography for diagnosis of single bone metastasis:comparison with bone scintigraphy. J Comput Assist Tomogr 2007;31:812-9. (Pubitemid 47482507)
101. Ozülker T, Küçüköz Uzun A, Ozülker F, Ozpaçac T Comparison of (18)F-FDG-PET/CT with (99m)Tc-MDP bone scintigraphy for the detection of bone metastases in cancer patients. Nucl Med Commun 2010;31:597-603.
102. Nakanishi K, Kobayashi M, Takahashi S et al. Whole body MRI for detecting metastatic bone tumoncomparison with bone scintigrams. Magn Reson Med Sci 2005;4:11-7.
103. Thomson V, Pialat JB, Gay F et al. Whole-body MRI for metastases screenings preliminary study using 3D VIBE sequences with automatic subtraction between noncontrast and contrast enhanced images. Am J Clin Oncol 2008;31:285-92
104. Nakanishi K, Kobayashi M, Nakaguchi K et al. Whole-body MRI for detecting metastatic bone tumour:diagnostic value of diffusion-weighted images. Magn Reson Med Sci 2007;6:147-55.
105. Gutzeit A, Doert A, Froehlich JM et al. Comparison of diffusion-weighted whole body MRI and skeletal scintigraphy for the detection of bone metastases in patients with prostate or breast carcinoma. Skeletal Radiol 2010;39:333-43.
106. Daldrup-Link HE, Franzius C, Link TM et al. Whole-body MR imaging for detection of bone metastases in children and young adults:comparison with skeletal scintigraphy and FDG PET. AJR Am J Roentgenol 2001;177(1):229-36. (Pubitemid 32578088)
107. Tsuya A, Kurata T, Tamura K et al. Skeletal metastases in non-small cell lung cancena retrospective study. Lung Cancer 2007;57:229-32. (Pubitemid 47044952)
108. Hetzel M, Arslandemir C, Konig HH et al. F-18 NaF PET for detection of bone metastases in lung cancer:accuracy, cost-effectiveness, and impact on patient management. J Bone Miner Res 2003;18:2206-14. (Pubitemid 37463314)
109. Bury T, Barreto A, Daenen F et al. Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer. Eur J Nucl Med 1998;25:1244-7. (Pubitemid 28446049)
110. Gayed I, Vu T, Johnson M, Macapinlac H et al. Comparison of bone and 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in the evaluation of bony metastases in lung cancer. Mol Imaging Biol 2003;5:26-31. (Pubitemid 36596542)
111. Hsia TC, Shen YY, Yen RF et al. Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium99m methylene diophosphate bone scan to detect bone metastases in patients with non-small cell lung cancer. Neoplasma 2002;49:267-71.
112. Marom EM, McAdams HP, Erasmus JJ et al. Staging non-small cell lung cancer with whole-body PET. Radiology 1999;212:803-9. (Pubitemid 29410986)
113. Cheran SK, Herndon JE 2nd, Patz EF Jr. Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer. Lung Cancer 2004;44:317-25. (Pubitemid 38609440)
114. Aflalo-Hazan V, Gutman F, Raileanu let al. 18F-FDG PET and bone scintigraphy to search for bone metastasis of lung cancer. Rev Pneumol Clin 2006;62:164-9. (Pubitemid 44046673)
115. Durski JM, Srinivas S, Segall G. Comparison of FDG-PET and bone scans for detecting skeletal metastases in patients with non-small cell lung cancer. Clin Positron Imaging 2000;397-105.
116. Krüger S, Buck AK, Mottaghy FM et al. Detection of bone metastases in patients with lung cancer.99mTc-MDP planar bone scintigraphy, 18F-fluoride PET or 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging 2009;36:1807-12.
117. Ak I, Sivrikoz MC, Entok E et al. Discordant findings in patients with non-small-cell lung cancer:absolutely normal bone scans versus disseminated bone metastases on positron-emission tomography/computed tomography. Eur J Cardiothorac Surg 2010;37:792-6.
118. Song JW, Oh YM, Shim TS et al. Efficacy comparison between (18)F-FDG PET/CT and bone scintigraphy in detecting bony metastases of non-small-cell lung cancer. Lung Cancer 2009;65:333-8.
119. Ohno Y, Koyama H, Takenaka D et al. Non-small cell lung cancer:whole-body MR examination for M-stage assessment - utility for whole-body diffusion-weighted imaging compared with integrated FDG PET/CT:comparison of accuracy of M-stage diagnosis for lung cancer patients. Radiology 2008;248.643-54.
120. Yi CA, Shin KM, Lee KS, Kim BT et al. Non-small cell lung cancer staging:efficacy comparison of integrated PET/CT versus 3.0-T whole-body MR imaging. Radiology 2008;248:632-42.
121. Takenaka D, Ohno Y, Matsumoto K et al. Detection of bone metastases in non-small cell lung cancer patients:comparison of whole-body diffusion-weighted imaging (DWI), whole-body MR imaging without and with DWI, whole-body FDG-PET/CT, and bone scintigraphy. J Magn Reson Imaging 2009;30:298-308.
122. Jacob T, Grahek D, Younsi N et al. Positron emission tomography with [18F]FDOPA and [18F]FDG in the imaging of small cell lung carcinoma:preliminary results. Eur J Nucl Med 2003;30:1266-9. (Pubitemid 37205382)
123. Tzannou IA, Karapanagiotou EM, Charpidou A et al. The use of radiolabeled somatostatin analog scintigraphy in the staging of small cell lung cancer patients. Am J Clin Oncol 2007;30:503-6. (Pubitemid 47537951)
124. Bradley JD, Dehdashti F, Mintun MA et al. Positron emission tomography in limited-stage small-cell lung cancer:a prospective study. J Clin Oncol 2004;22:3248-54. (Pubitemid 41103679)
125. Kamel EM, Zwahlen D, Wyss MT et al. Whole-body (18)F-FDG PET improves the management of patients with small cell lung cancer. J Nucl Med 2003;44:1911-7. (Pubitemid 40022136)
126. Brink I, Schumacher T, Mix M et al. Impact of [18F)FDG-PET on the primary staging of small-cell lung cancer. Eur J Nucl Med Mol Imaging 2004;31:1614-20. (Pubitemid 40104607)
127. Hess KR, Varadhachary GR, Taylor SH et al. Metastatic patterns in adenocarcinoma. Cancer 2006;106:1624-33.
128. Rapiti E, Verkooijen HM, Vlastos G et al. Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis. J Clin Oncol 2006;24:2743-9. (Pubitemid 46630571)
129. Shien T, Kinoshita T, Shimizu C et al. Primary tumor resection improves the survival of younger patients with metastatic breast cancer. Oncol Rep 2009;21:827-32.
130. Briasoulis E, Karavasilis V, Kostadima Let al. Metastatic breast carcinoma confined to bone:Portrait of a clinical entity. Cancer 2004;101:1524-8. (Pubitemid 39318897)
131. Yamashita K, Koyama H, Inaji H. Prognostic significance of bone metastasis from breast cancer. Clin Orthop Related Res 1995;312:89-94.
132. Solomayer EF, Diel IJ, Meyberg GC et al. Metastatic breast cancer:clinical course, prognosis and therapy related to the first site of metastasis. Breast Cancer Res Treat 2000;59:271-8. (Pubitemid 30243049)
133. Park W, Huh SJ, Yang JH et al. The implication of hot spots on bone scans within the irradiated field of breast cancer patients treated with mastectomy followed by radiotherapy. Ann Nucl Med 2008;22:685-91.
134. Schirrmeister H, Guhlmann A, Kotzerke J et al. Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. J Clin Oncol 1999;17:2381-2389. (Pubitemid 29368236)
135. 18FDG PET:differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol 1998;16:3375-9.
136. Moon DH, Maddahi J, Silverman DH et al. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma. J Nucl Med 1998;39:431-5. (Pubitemid 28136839)
137. Gallowitsch HJ, Kresnik E, Gasser J et al. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma:a comparison to conventional imaging. Invest Radiol 2003;38:250-6. (Pubitemid 36535030)
138. Yang SN, Liang JA, Lin FJ et al. Comparing whole body (18) F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphonate bone scan to detect bone metastases in patients with breast cancer. J Cancer Res Clin Oncol 2002;128:325-8.
139. Rǎ;ileanu I, Rusu V, Talbot JN et al. Correlation in imaging techniques for the early detection of bone metastases in a case of breast cancer. Rev Med Chir Soc Med Nat Iasi 2004;108:210-3.
140. Dose J, Bleckmann C, Bachmann S et al. Comparison of fluorodeoxyglucose positron emission tomography and "conventional diagnostic procedures" for the detection of distant metastases in breast cancer patients. Nucl Med Commun 2002;23:857-64.
141. Nakai T, Okuyama C, Kubota T et al. Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer. Eur J Nucl Med Mol Imaging 2005;32:1253-8. (Pubitemid 41598715)
142. Fuster D, Duch J, Paredes P et al. Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. J Clin Oncol 2008;26:4746-51.
143. Morris PG, Lynch C, Feeney JN et al. Integrated positron emission tomography/computed tomography may render bone scintigraphy unnecessary to investigate suspected metastatic breast cancer. J Clin Oncol 2010;28:3154-9.
144. Mintun MA, Welch MJ, Siegel BA et al. Breast cancer.PET imaging of estrogen receptors. Radiology 1988;169:45-8.
145. McGuire AH, Dehdashti F, Siegel BA, et al. Positron tomographic assessment of 16 alpha-[18F] fluoro-17 beta-estradiol uptake in metastatic breast carcinoma. J Nucl Med 1991;32:1526-31.
146. Dehdashti F, Flanagan FL, Mortimer JE et al. Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nucl Med 1999;26:51-6. (Pubitemid 29137739)
147. Sundararajan L, Linden HM, Link JM et al. 18F-Fluoroestradiol. Semin Nucl Med 2007;37:470-6.
148. Heusner TA, Kuemmel S, Koeninger A et al. Diagnostic value of diffusion-weighted magnetic resonance imaging (DWI) compared to FDG PET/CT for whole-body breast cancer staging. Eur J Nucl Med Mol Imaging 2010;37:1077-86.
149. Nørgaard M, Jensen AØ, Jacobsen JB et al. Skeletal related events, bone metastasis and survival of prostate cancer:a population based cohort study in Denmark (1999 to 2007). J Urol 2010;184:162-7.
150. Paycha F, Ramadan A, Akrout L, et al. Métastases osseuses du cancer de la prostate et scintigraphie osseuse. Méd Nucl 2005;29:501-40. (Pubitemid 41625796)
151. 18F-Fluoride PET/CT. J Nucl Med 2006;47:287-97.
152. Shreve PD, Grossman HB, Gross MD, et al. Metastatic prostate cancer.initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. Radiology 1996;199:751-6.
153. Yeh SD, Imbriaco M, Larson SM et al. Detection of bony metastases of androgen-independent prostate cancer by PET-FDG. Nucl Med Biol 1996;23:693-7. (Pubitemid 26342473)
154. Morris MJ, Akhurst T, Osman I et al. Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology 2002;59:913-8. (Pubitemid 34522186)
155. Kwee SA, De Grado Tr, Talbot JN et al. Cancer imaging with fluorine-18-labeled choline derivatives. Semin Nucl Med 2007;37:420-8.
156. Talbot JN, Gutman F, Huchet V et al. Clinical usefulness of positron emission tomography in prostate cancer. Presse Med 2007;36 (12 Pt 2):1794-806. (Pubitemid 350137670)
157. Beheshti M, Vali R, Waldenberger P et al. The use of F-18 choline PET in the assessment of bone metastases in prostate cancencorrelation with morphological changes on CT. Mol Imaging Biol 2009;1:446-54.
158. Venkitaraman R, Cook GJ, Dearnaley DP et al. Whole-body magnetic resonance imaging in the detection of skeletal metastases in patients with prostate cancer. J Med Imaging Radiat Oncol 2009;53:241-7.
159. Oyama N, Miller TR, Dehdashti F et al. 11C-acetate PET imaging of prostate cancer detection of recurrent disease at PSA relapse. J Nucl Med 2003;44.549-55.
160. Wachter S, Tomek S, Kurtaran A et al. 11C-acetate positron emission tomography imaging and image fusion with computed tomography and magnetic resonance imaging in patients with recurrent prostate cancer. J Clin Oncol 2006;24:2513-9. (Pubitemid 46630628)
161. Fricke E, Machtens S, Hofmann M et al. Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients. Eur J Nucl Med Mol Imaging 2003;30:607-11. (Pubitemid 36559841)
162. Cimitan M, Bortolus R, Morassut S et al. [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse:experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging 2006;33:1387-98. (Pubitemid 44885404)
163. Larson SM, Morris M, Gunther I et al. Tumor localization of 16 beta-18F-fluoro-5 alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med 2004;45:366-73. (Pubitemid 47618608)
164. Eschmann SM, Pfannenberg AC, Rieger A et al. Comparison of 11C-choline-PET/CT and whole body-MRI for staging of prostate cancer. Nuklearmedizin 2007;46:161-8. (Pubitemid 47612279)
165. Schlumberger M, Tubiana M, De Vathaire F et al. Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrin Metab 1986,63.960-7.
166. Muresan MM, Olivier P, Leclère J et al. Bone metastases from differentiated thyroid carcinoma. Endocr Relat Cancer 2008;15:39-43.
167. Urhan M, Dadparvar S, Mavi A et al. Iodine-123 as a diagnostic imaging agent in differentiated thyroid carcinoma:a comparison with iodine-131 post-treatment scanning and serum thyroglobulin measurement. Eur J Nucl Med Mol Imaging 2007;34:1012-7. (Pubitemid 46919552)
168. Barwick T, Murray I, Megadmi H et al. Single photon emission computed tomography (SPECD/computed tomography using Iodine-123 in patients with differentiated thyroid cancer:additional value over whole body planar imaging and SPECT. Eur J Endocrinol 2010;162:1131-9.
169. Freudenberg LS, Antoch G, Jentzen W et al. Value of (124)I-PET/CT in staging of patients with differentiated thyroid cancer. Eur Radiol 2004;14:2092-8. (Pubitemid 39481183)
170. Phan HT, Jager PL, Paans AM et al. The diagnostic value of 124I-PET in patients with differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2008;35.958-65.
171. Capoccetti F, Criscuoli B, Rossi G et al. The effectiveness of 124I PET/CT in patients with differentiated thyroid cancer. Q J Nucl Med Mol Imaging 2009:53:536-45.
172. Alam MS, Takeuchi R, Kasagi K et al. Value of combined technetium-99m hydroxy methylene diphosphonate and thallium-201 imaging bone metastases from thyroid carcinoma. Thyroid 1997;7:705-12. (Pubitemid 28086201)
173. Iwata M, Kasagi K, Misaki T et al. Comparison of whole-body 18F-FDG PET, 99mTc-MIBI SPET, and post-therapeutic 131I-Na scintigraphy in the detection of metastatic thyroid cancer. Eur J Nucl Med Mol Imaging 2004;31:491-8. (Pubitemid 38461563)
174. Robbins RJ, Wan Q, Grewal RK et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 2006;91:498-505. (Pubitemid 43236915)
175. Moog F, Linke R, Manthey N et al. Influence of thyroid stimulating hormone levels on uptake of FDG in recurrent and metastatic differentiated thyroid carcinoma. J Nucl Med 2000;41:1989-95. (Pubitemid 32038687)
176. Petrich T, Börner AR, Hofmann OM, Knapp WH. Influence of rTSH on [18F] fluorodeoxyglucose uptake by differentiated carcinoma. Eur J Nucl Med 2002;29:641-7. (Pubitemid 34439324)
177. Chin BB, Patel P, Cohade C et al. Recombinant human thyrotropin stimulation of fluoro-D-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma. J Clin Endocrinol Metab 2004;89.91-5.
178. Ito S, Kato K, Ikeda M et al. Comparison of 18F-FDG PET and bone scintigraphy in detection of bone metastases of thyroid cancer. J Nucl Med 2007;48.889-95.
179. Feine U, Lietzenmayer R, Hanke JP et al. Fluorine 18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med 1996;37:1468-72. (Pubitemid 26321624)
180. Oh JR, Byun BH, Hong SP et al. Comparison of (131)I whole-body imaging, (131)I SPECT/CT, and (18)F-FDG PET/CT in the detection of metastatic thyroid cancer. Eur J Nucl Med Mol Imaging 2011 [Epub ahead of print].
181. Freudenberg LS, Antoch G, Frilling A et al. Combined metabolic and morphologic imaging in thyroid carcinoma patients with elevated serum thyroglobulin and negative cervical ultrasonography:role of 124I-PET/CT and FDG-PET. Eur J Nucl Med Mol Imaging 2008;35:950-7.
182. Liu FY, Chang JT, Wang HM et al. [18F]fluorodeoxyglucose positron emission tomography is more sensitive than skeletal scintigraphy for detecting bone metastasis in endemic nasopharyngeal carcinoma at initial staging. J Clin Oncol 2006;24:599-604. (Pubitemid 46630422)
183. Liu FY, Lin CY, Chang JT et al. 18F-FDG PET can replace conventional work-up in primary M staging of nonkeratinizing nasopharyngeal carcinoma. J Nucl Med 2007;48:1614-9. (Pubitemid 47572708)
184. Ng SH, Chan SC, Yen TC et al. Staging of untreated nasopharyngeal carcinoma with PET/CT:comparison with conventional imaging work-up. Eur J Nucl Med Mol Imaging 2009;36:12-22.
185. Fottner A, Szalantzy M, Wirthmann L et al. Bone metastases from renal cell carcinoma:patient survival after surgical treatment. BMC Musculoskelet Disord 2010;11:145.
186. Wu HC, Yen RF, Shen YY et al. Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphate bone scan to detect bone metastases in patients with renal cell carcinomas - a preliminary report. J Cancer Res Clin Oncol 2002;128:503-6.
187. Kang DE, White RL Jr, Zuger JH et al. Clinical use of fluorode-oxyglucose F 18 positron emission tomography for detection of renal cell carcinoma. J Urol 2004;171:1806-9. (Pubitemid 38501007)
188. Park JW, Jo MK, Lee HM. Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma. BJU Int 2009;103.615-9.
189. Sohaib SA, Cook G, Allen SD et al. Comparison of whole-body MRI and bone scintigraphy in the detection of bone metastases in renal cancer. Br J Radiol 2009:82:632-9.
190. Lodde M, Lacombe L, Friede J et al. Evaluation of fluorodeoxyglucose positron-emission tomography with computed tomography for staging of urothelial carcinoma. BJU Int 2010;106.658-63.
191. Quint LE, Hepburn LM, Francis IR et al. Incidence and distribution of distant metastases from newly diagnosed esophageal carcinoma. Cancer 1995;76:1120-5.
192. Kato H, Miyazaki T, Nakajima M et al. Comparison between whole-body positron emission tomography and bone scintigraphy in evaluating bony metastases of esophageal carcinomas. Anticancer Res 2005;25(6C):4439-44. (Pubitemid 41729493)
193. Yoshioka T, Yamaguchi K, Kubota K et al. Evaluation of 18F-FDG PET in patients with advanced, metastatic, or recurrent gastric cancer. J Nucl Med 2003;44.690-9.
194. Roth ES, Fetzer DT, Barron BJ et al. Does colon cancer ever metastasize to bone first? a temporal analysis of colorectal cancer progression. BMC Cancer 2009,9:274.
195. Squillaci E, Manenti G, Mancino S et al. Staging of colon cancer:whole-body MRI vs. whole-body PET-CT- initial clinical experience. Abdom Imaging. 2008;33:676-88.
196. Yen RF, Chen CY, Cheng MF et al. The diagnostic and prognostic effectiveness of F-18 sodium fluoride PET-CT in detecting bone metastases for hepatocellular carcinoma patients. Nucl Med Commun 2010;31:637-45.
197. Sugiyama M, Sakahara H, Torizuka T et al. 18F-FDG PET in the detection of extrahepatic metastases from hepatocellular carcinoma. J Gastroenterol 2004:39:961-8. (Pubitemid 39490173)
198. Nagaoka S, Itano S, Ishibashi M et al. Value of fusing PET plus CT images in hepatocellular carcinoma and combined hepatocellular and cholangiocarcinoma patients with extrahepatic metastases:preliminary findings. Liver Int 2006;26:781-8. (Pubitemid 44165245)
199. Yoon KT, Kim JK, Lim do Y et al. Role of 18F-fluorodeoxyglucose positron emission tomography in detecting extrahepatic metastasis in pretreatment staging of hepatocellular carcinoma. Oncology 2007;72 Suppl 1:104-10. (Pubitemid 350256673)
200. Kim YK, Lee KW, Cho SY et al. Usefulness 18F-FDG positron emission tomography/computed tomography for detecting recurrence of hepatocellular carcinoma in posttransplant patients. Liver Transpl 2010;16.767-72.
201. Wakabayashi H, Nishiyama Y, Otani T et al. Role of 18F-fluorodeoxyglucose positron emission tomography imaging in surgery for pancreatic cancer. World J Gastroenterol 2008;14:64-9. (Pubitemid 351314328)
202. Kauhanen SP, Komar G, Seppänen MP et al. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer. Ann Surg 2009;250.957-63.
203. Park JW, Kim JH, Kim SK et al. A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma. J Nucl Med 2008;49:1912-21.
204. Ho CL, Chen S, Cheng TK et al. PET/CT characteristics of isolated bone metastases in hepatocellular carcinoma. Radiology 2011;258:515-23.
205. Talbot JN, Fartoux L, Balogova S et al. Detection of hepatocellular carcinoma with PET/CT:A prospective comparison of 18F-Fluorocholine and 18F-FDG in patients with cirrhosis or chronic liver disease. J Nucl Med 2010;51:1699-706.
206. Liu FY, Yen TC, Chen MY et al. Detection of hematogenous bone metastasis in cervical cancer: 18F-fluorodeoxyglucose-positron emission tomography versus computed tomography and magnetic resonance imaging. Cancer 2009;115(23):5470-80.
207. Pfannenberg C, Aschoff P, Schanz S et al. Prospective comparison of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma. Eur J Cancer 2007;43:557-64. (Pubitemid 46177588)
208. Laurent V, Trausch G, Bruot O et al. Comparative study of two whole-body imaging techniques in the case of melanoma metastases:advantages of multi-contrast MRI examination including a diffusion-weighted sequence in comparison with PET-CT. Eur J Radiol 2010;75:376-83.
209. Panzuto F, Nasoni S, Falconi M et al. Prognostic factors and survival in endocrine tumor patients:comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer 2005;12:1083-92. (Pubitemid 41815799)
210. Lebtahi R, Cadiot G, Delahaye N et al. Detection of bone metastases in patients with endocrine gastroenteropancreatic tumors:bone scintigraphy compared with somatostatin receptor scintigraphy. J Nucl Med 1999;40:1602-8. (Pubitemid 29471148)
211. Adams S, Baum R, Rink T et al. Limited value of FDG PET for the imaging of NET. Eur J Nucl Med 1998;25:79-83.
212. Montravers F, Grahek D, Kerrou K et al. Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors? J Nucl Med 2006;47:1455-62. (Pubitemid 47544931)
213. Montravers F, Kerrou K, Nataf V et al. Impact of fluorodihydroxyphenylalanine-18F positron emission tomography on management of adult patients with documented or occult digestive endocrine tumors. J Clin Endocrinol Metab 2009;94:1295-301.
214. Talbot JN, Kerrou K, Missoum F et al. 6-[F-18]fluoro-L-DOPA positron emission tomography in the imaging of Merkel cell carcinoma:preliminary report of three cases with 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography or pentetreotide-(111In) SPECT data. Mol Imaging Biol 2005;7:257-61.
215. Peloschek P, Novotny C, Mueller-Mang C et al. Diagnostic imaging in Merkel cell carcinoma:lessons to learn from 16 cases with correlation of sonography, CT, MRI and PET. Eur J Radiol 2010;73:317-23.
216. Timmers HJ, Kozupa A, Chen CC et al. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. J Clin Oncol 2007;25:2262-9. (Pubitemid 46954653)
217. Gabriel M, Decristoforo C, Kendler D et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors:comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007;48:508-18. (Pubitemid 47571404)
218. Srirajaskanthan R, Kayani I, Quigley AM et al. The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy. J Nucl Med 2010;51:875-82.
219. Becherer A, Szabó M, Karanikas G et al. Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET. J Nucl Med 2004;45:1161-7. (Pubitemid 47611661)
220. Putzer D, Gabriel M, Henninger B et al. Bone metastases in patients with neuroendocrine tumor:68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy. J Nucl Med 2009;50:1214-21.
221. Ambrosini V, Nanni C, Zompatori M et al. (68)Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2010;37:722-7.
222. Leboulleux S, Dromain C, Vataire AL et al. Prediction and diagnosis of bone metastases in well-differentiated gastro-entero-pancreatic endocrine cancer:a prospective comparison of whole body magnetic resonance imaging and somatostatin receptor scintigraphy. J Clin Endocrinol Metab 2008;93:3021-8.
223. Zuetenhorst JM, Hoefnageli CA, Boot H et al. Evaluation of (111)In-pentetreotide, (131)I-MIBG and bone scintigraphy in the detection and clinical management of bone metastases in carcinoid disease. Nucl Med Commun 2002;23:735-41. (Pubitemid 34837003)
224. Meijer WG, van der Veer E, Jager PL et al. Bone metastases in carcinoid tumors: clinical features, imaging characteristics, and markers of bone metabolism. J Nucl Med 2003;44:184-91.
225. Giraudet AL, Vanel D, Leboulleux S et al. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metab 2007;92:4185-90. (Pubitemid 350074730)
226. Oudoux A, Salaun PY, Bournaud C et al. Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy. J Clin Endocrinol Metab 2007;92:4590-7. (Pubitemid 350223431)
227. Koopmans KP, de Groot JWB, Plukke JTM et al. 18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer:relation to tumor differentiation. J Nucl Med 2008;49:524-31. (Pubitemid 351520599)
228. Beheshti M, Pöcher S, Vali R et al. The value of (18)F-DOPA PET-CT in patients with medullary thyroid carcinoma:comparison with (18)F-FDG PET-CT. Eur Radiol 2009;19:1425-34.
229. Luster M, Karges W, Zeich K et al. Clinical value of 18-fluorine- fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma. Thyroid 2010;20:527-33.
230. Conry BG, Papathanasiou ND, Prakash V et al. Comparison of (68)Ga-DOTATATE and (18)Ffluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2010;37:49-57.
231. Inoue T, Yoshinaga K, Morita K et al. Whole-body iodine-131 metaiodobenzylguanidine imaging for detection of bone metastases in patients with paraganglioma:comparison with bone scintigraphy. Ann Nucl Med 2007;21:307-10. (Pubitemid 350104521)
232. Takano A, Oriuchi N, Tsushima Y et al. Detection of metastatic lesions from malignant pheochromocytoma and paraganglioma with diffusion-weighted magnetic resonance imaging:comparison with 18F-FDG positron emission tomography and 123I-MIBG scintigraphy. Ann Nucl Med 2008;22:395-401. (Pubitemid 351938512)
233. Naji M, Zhao C, Welsh SJ et al. (68)Ga-DOTA-TATE PET vs. (123)I-MIBG in identifying malignant neural crest tumours. Mol Imaging Biol 2010 [Epub ahead of print).
234. Zelinka T, Timmers HJ, Kozupa A et al. Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma:specific implications for succinate dehydrogenase enzyme subunit B gene mutations. Endocr Relat Cancer 2008;15:311-23. (Pubitemid 351449749)
235. Timmers HJ, Chen CC, Carrasquillo JA et al. Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J Clin Endocrinol Metab 2009;94:4757-67.
236. 18F DOPA whole-body PET - Initial results. Radiology 2002;222:507-12.
237. Fottner C, Helisch A, Anlauf M et al. 6-18F-fluoro-L- dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas:correlation with vesicular monoamine transporter expression. J Clin Endocrinol Metab 2010;95:2800-10.
238. 18F]FDOPA-PET in the localization of extra-adrenal paragangliomas:the case for a patient-tailored use of nuclear imaging modalities. Clin Endocrinol (Oxf) 2011;74:21-9.
239. Gordon I, Peters AM, Gutman A et al. Skeletal assessment in neuroblastoma:the pitfalls of iodine-123-MIBG scans. J Nucl Med 1990;31:129-34. (Pubitemid 20059210)
240. Troncone L, Rufini V, Montemaggi P et al. The diagnostic and therapeutic utility of radioiodinated metaiodobenzylguanidine (MIBG):5 years of experience. Eur J Nucl Med 1990;16:325-35. (Pubitemid 20283547)
241. Pfluger T, Schmied C, Porn U et al. Integrated imaging using MRI and 123I metaiodobenzylguanidine scintigraphy to improve sensitivity and specificity in the diagnosis of pediatric neuroblastoma. AJR Am J Roentgenol 2003;181:1115-24. (Pubitemid 37151800)
242. Corbett R, Olliff J, Fairley N et al. A prospective comparison between magnetic resonance imaging, meta-iodobenzylguanidine scintigraphy and marrow histology/cytology in neuroblastoma. Eur J Cancer 1991;27:1560-4.
243. Bourliere Najean B, Siles S, Panuel M et al. Value of MRI and MIBG-I123 scintigraphy in the diagnosis of spinal bone marrow involvement in neuroblastoma in children. Pediatr Radiol 1992;22:443-6.
244. Lebtahi N, Gudinchet F, Nenadov-Beck M et al. Evaluating bone marrow metastasis of neuroblastoma with iodine-123-MIBG scintigraphy and MRI. J Nucl Med 1997;38:1389-92. (Pubitemid 27386197)
245. Kushner BH, Yeung HW, Larson SM et al. Extending positron emission tomography scan utility to high-risk neuroblastoma:fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients. J Clin Oncol 2001;19:3397-405. (Pubitemid 32642193)
246. Sharp SE, Shulkin BL, Gelfand MJ et al. 123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma. J Nucl Med 2009;50:1237-43.
247. Kumar J, Seith A, Kumar A et al. Whole-body MR imaging with the use of parallel imaging for detection of skeletal metastases in pediatric patients with small-cell neoplasms:comparison with skeletal scintigraphy and FDG PET/CT. Pediatr Radiol 2008;38:953-62.
248. Paycha F, Girma A. Pattern-oriented approach in hybrid imaging (bisphosphonates-(99mTc) SPECT/CT and FIuoride-(18F) PET/CT) according to bone abnormality phenotype:the sclerotic/osteoblastic lesion and the osteolytic/osteoclastic lesion. Med Nucl 2011;35:332-5.
249. Cherry SR. Multimodality imaging:beyond PET/CT and SPECT/CT. Semin Nucl Med 2009;39:348-53.
250. von Schulthess GK, Schlemmer HP. A look ahead: PET/MR versus PET/CT. Eur J Nucl Med Mol Imaging 2009;36 Suppl 1:S3-9.
251. Boss A, Stegger L, Bisdas S et al. Feasibility of simultaneous PET/MR imaging in the head and upper neck area. Eur Radiol 2011 [Epub ahead of print).